Organoid development in cancer genome discovery

Current Opinion in Genetics and Development

Volumn 30, Issue , 2015, Pages 42-48

  Gao, Dong ^a   Chen, Yu ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENIGN ORGANOID CULTURE; CANCER CELL CULTURE; CANCER GENETICS; CANCER ORGANOID CULTURE; CELL CULTURE; CELL HETEROGENEITY; CONDITIONAL REPROGRAMMED CELL; CULTURE TECHNIQUE; CYTOPLASM; GENE DELETION; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PATIENT DERIVED XENOGRAFT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; MALE; NEOPLASMS; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; HUMANS; MALE; NEOPLASMS; ORGANOIDS; PRECISION MEDICINE; PROSTATIC NEOPLASMS;

EID: 84936929290     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2015.02.007     Document Type: Review

References (50)

1. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., Thongprasert S., Tan E.H., Pemberton K., Archer V., Carroll K. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (iressa survival evaluation in lung cancer). Lancet 2005, 366:1527-1537.
2. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., Palmero R., Garcia-Gomez R., Pallares C., Sanchez J.M., Porta R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (eurtac): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
3. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., Nishiwaki Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
4. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., Geater S.L., Orlov S., Tsai C.M., Boyer M., Su W.C., et al. Phase iii study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
5. Wu Y.L., Zhou C., Hu C.P., Feng J., Lu S., Huang Y., Li W., Hou M., Shi J.H., Lee K.Y., Xu C.R., et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (lux-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:213-222.
6. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crino L., Ahn M.J., De Pas T., Besse B., Solomon B.J., Blackhall F., Wu Y.L., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368:2385-2394.
7. Shaw A.T., Ou S.H., Bang Y.J., Camidge D.R., Solomon B.J., Salgia R., Riely G.J., Varella-Garcia M., Shapiro G.I., Costa D.B., Doebele R.C., et al. Crizotinib in ros1-rearranged non-small-cell lung cancer. N Engl J Med 2014.
8. Skloot R. The immortal life of Henrietta lacks 2010, Crown Publishers, New York.
9. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
10. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
11. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004, 101:13306-13311.
12. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., Golub T.R., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
13. McDermott U., Sharma S.V., Dowell L., Greninger P., Montagut C., Lamb J., Archibald H., Raudales R., Tam A., Lee D., Rothenberg S.M., et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A 2007, 104:19936-19941.
14. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., Liu Q., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
15. Olivotto M., Dello Sbarba P. Environmental restrictions within tumor ecosystems select for a convergent, hypoxia-resistant phenotype of cancer stem cells. Cell Cycle 2008, 7:176-187.
16. O'Driscoll L., Gammell P., McKiernan E., Ryan E., Jeppesen P.B., Rani S., Clynes M. Phenotypic and global gene expression profile changes between low passage and high passage min-6 cells. J Endocrinol 2006, 191:665-676.
17. Hidalgo M., Amant F., Biankin A.V., Budinska E., Byrne A.T., Caldas C., Clarke R.B., de Jong S., Jonkers J., Maelandsmo G.M., Roman-Roman S., et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 2014, 4:998-1013.
18. Tentler J.J., Tan A.C., Weekes C.D., Jimeno A., Leong S., Pitts T.M., Arcaroli J.J., Messersmith W.A., Eckhardt S.G. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9:338-350.
19. Hidalgo M., Bruckheimer E., Rajeshkumar N.V., Garrido-Laguna I., De Oliveira E., Rubio-Viqueira B., Strawn S., Wick M.J., Martell J., Sidransky D. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Mol Cancer Ther 2011, 10:1311-1316.
20. Lawrence M.G., Taylor R.A., Toivanen R., Pedersen J., Norden S., Pook D.W., Frydenberg M., Australian Prostate Cancer B, Papargiris M.M., Niranjan B., Richards M.G., et al. A preclinical xenograft model of prostate cancer using human tumors. Nat Protoc 2013, 8:836-848.
21. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., Factor R., Matsen C., Milash B.A., Nelson E., Neumayer L., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med 2011, 17:1514-1520.
22. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 1961, 25:585-621.
23. Liu X., Ory V., Chapman S., Yuan H., Albanese C., Kallakury B., Timofeeva O.A., Nealon C., Dakic A., Simic V., Haddad B.R., et al. Rock inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012, 180:599-607.
24. Chapman S., Liu X., Meyers C., Schlegel R., McBride A.A. Human keratinocytes are efficiently immortalized by a Rho kinase inhibitor. J Clin Invest 2010, 120:2619-2626.
25. Yuan H., Myers S., Wang J., Zhou D., Woo J.A., Kallakury B., Ju A., Bazylewicz M., Carter Y.M., Albanese C., Grant N., et al. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N Engl J Med 2012, 367:1220-1227.
26. Crystal A.S., Shaw A.T., Sequist L.V., Friboulet L., Niederst M.J., Lockerman E.L., Frias R.L., Gainor J.F., Amzallag A., Greninger P., Lee D., et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 2014, 346:1480-1486.
27. Sato T., Vries R.G., Snippert H.J., van de Wetering M., Barker N., Stange D.E., van Es J.H., Abo A., Kujala P., Peters P.J., Clevers H. Single lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009, 459:262-265.
28. Lancaster M.A., Knoblich J.A. Organogenesis in a dish: modeling development and disease using organoid technologies. Science 2014, 345:1247125.
29. Schwank G., Koo B.K., Sasselli V., Dekkers J.F., Heo I., Demircan T., Sasaki N., Boymans S., Cuppen E., van der Ent C.K., Nieuwenhuis E.E., et al. Functional repair of CFTR by crispr/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell 2013, 13:653-658.
30. Sato T., Stange D.E., Ferrante M., Vries R.G., Van Es J.H., Van den Brink S., Van Houdt W.J., Pronk A., Van Gorp J., Siersema P.D., Clevers H. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 2011, 141:1762-1772.
31. Barker N., Huch M., Kujala P., van de Wetering M., Snippert H.J., van Es J.H., Sato T., Stange D.E., Begthel H., van den Born M., Danenberg E., et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell 2010, 6:25-36.
32. Huch M., Dorrell C., Boj S.F., van Es J.H., Li V.S., van de Wetering M., Sato T., Hamer K., Sasaki N., Finegold M.J., Haft A., et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature 2013, 494:247-250.
33. Taguchi A., Kaku Y., Ohmori T., Sharmin S., Ogawa M., Sasaki H., Nishinakamura R. Redefining the in vivo origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. Cell Stem Cell 2014, 14:53-67.
34. Xia Y., Nivet E., Sancho-Martinez I., Gallegos T., Suzuki K., Okamura D., Wu M.Z., Dubova I., Esteban C.R., Montserrat N., Campistol J.M., et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells. Nat Cell Biol 2013, 15:1507-1515.
35. Takasato M., Er P.X., Becroft M., Vanslambrouck J.M., Stanley E.G., Elefanty A.G., Little M.H. Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. Nat Cell Biol 2014, 16:118-126.
36. Antonica F., Kasprzyk D.F., Opitz R., Iacovino M., Liao X.H., Dumitrescu A.M., Refetoff S., Peremans K., Manto M., Kyba M., Costagliola S. Generation of functional thyroid from embryonic stem cells. Nature 2012, 491:66-71.
37. Koehler K.R., Mikosz A.M., Molosh A.I., Patel D., Hashino E. Generation of inner ear sensory epithelia from pluripotent stem cells in 3d culture. Nature 2013, 500:217-221.
38. Eiraku M., Takata N., Ishibashi H., Kawada M., Sakakura E., Okuda S., Sekiguchi K., Adachi T., Sasai Y. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature 2011, 472:51-56.
39. Suga H., Kadoshima T., Minaguchi M., Ohgushi M., Soen M., Nakano T., Takata N., Wataya T., Muguruma K., Miyoshi H., Yonemura S., et al. Self-formation of functional adenohypophysis in three-dimensional culture. Nature 2011, 480:57-62.
40. Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P., Knoblich J.A. Cerebral organoids model human brain development and microcephaly. Nature 2013, 501:373-379.
41. Karthaus W.R., Iaquinta P.J., Drost J., Gracanin A., van Boxtel R., Wongvipat J., Dowling C.M., Gao D., Begthel H., Sachs N., Vries R.G., et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 2014, 159:163-175.
42. Boj S.F., Hwang C.I., Baker L.A., Chio I.I., Engle D.D., Corbo V., Jager M., Ponz-Sarvise M., Tiriac H., Spector M.S., Gracanin A., et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 2015, 160:324-338.
43. Goldstein A.S., Huang J., Guo C., Garraway I.P., Witte O.N. Identification of a cell of origin for human prostate cancer. Science 2010, 329:568-571.
44. Wang X., Kruithof-de Julio M., Economides K.D., Walker D., Yu H., Halili M.V., Hu Y.P., Price S.M., Abate-Shen C., Shen M.M. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009, 461:495-500.
45. Choi N., Zhang B., Zhang L., Ittmann M., Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell 2012, 21:253-265.
46. Gao D., Vela I., Sboner A., Iaquinta P.J., Karthaus W.R., Gopalan A., Dowling C., Wanjala J.N., Undvall E.A., Arora V.K., Wongvipat J., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014, 159:176-187.
47. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., Asangani I.A., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
48. De Mattos-Arruda L., Cortes J., Santarpia L., Vivancos A., Tabernero J., Reis-Filho J.S., Seoane J. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013, 10:377-389.
49. Ozkumur E., Shah A.M., Ciciliano J.C., Emmink B.L., Miyamoto D.T., Brachtel E., Yu M., Chen P.I., Morgan B., Trautwein J., Kimura A., et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013, 5:179ra147.
50. Yu M., Bardia A., Aceto N., Bersani F., Madden M.W., Donaldson M.C., Desai R., Zhu H., Comaills V., Zheng Z., Wittner B.S., et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014, 345:216-220.